Yamin Shu

1.2k total citations
42 papers, 872 citations indexed

About

Yamin Shu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Yamin Shu has authored 42 papers receiving a total of 872 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in Yamin Shu's work include Cancer Immunotherapy and Biomarkers (6 papers), Gastric Cancer Management and Outcomes (5 papers) and PARP inhibition in cancer therapy (5 papers). Yamin Shu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Gastric Cancer Management and Outcomes (5 papers) and PARP inhibition in cancer therapy (5 papers). Yamin Shu collaborates with scholars based in China, Japan and Australia. Yamin Shu's co-authors include Qilin Zhang, Xu‐Cheng He, Pan Wu, Yufeng Ding, Yanxin Liu, Qilin Zhang, Juan Li, Kaiping Wang, Guosong Chen and Ziming Zheng and has published in prestigious journals such as PLoS ONE, Scientific Reports and Carbohydrate Polymers.

In The Last Decade

Yamin Shu

37 papers receiving 857 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yamin Shu China 17 223 207 175 156 133 42 872
Yufeng Ding China 13 80 0.4× 120 0.6× 65 0.4× 95 0.6× 78 0.6× 26 509
Maobai Liu China 17 33 0.1× 225 1.1× 97 0.6× 162 1.0× 116 0.9× 87 815
H. T. Schneider Germany 24 120 0.5× 552 2.7× 108 0.6× 796 5.1× 1.1k 8.0× 61 1.6k
Sooyoung Shin South Korea 16 18 0.1× 119 0.6× 67 0.4× 150 1.0× 134 1.0× 58 947
Hervé Le Louët France 13 216 1.0× 43 0.2× 512 2.9× 21 0.1× 87 0.7× 28 994
Ikuya Miki Japan 19 23 0.1× 309 1.5× 44 0.3× 323 2.1× 548 4.1× 65 1.1k
Vasco A. J. Maria Portugal 11 38 0.2× 130 0.6× 86 0.5× 32 0.2× 34 0.3× 26 658
Andreas Benesic Germany 17 14 0.1× 141 0.7× 57 0.3× 56 0.4× 152 1.1× 30 1.1k
Xuemin Jiang United States 10 10 0.0× 207 1.0× 106 0.6× 123 0.8× 44 0.3× 15 803
Anton Gillessen Germany 14 9 0.0× 96 0.5× 65 0.4× 221 1.4× 260 2.0× 50 905

Countries citing papers authored by Yamin Shu

Since Specialization
Citations

This map shows the geographic impact of Yamin Shu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yamin Shu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yamin Shu more than expected).

Fields of papers citing papers by Yamin Shu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yamin Shu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yamin Shu. The network helps show where Yamin Shu may publish in the future.

Co-authorship network of co-authors of Yamin Shu

This figure shows the co-authorship network connecting the top 25 collaborators of Yamin Shu. A scholar is included among the top collaborators of Yamin Shu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yamin Shu. Yamin Shu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
4.
Shu, Yamin, et al.. (2025). Sorafenib and ponatinib as effective inhibitors of Fusobacterium nucleatum FtsZ: An in silico and in vitro study. International Journal of Biological Macromolecules. 330(Pt 4). 148363–148363.
5.
Shu, Yamin, Fang Cheng, Gang Nie, et al.. (2025). A novel method to quantify Dendrobium officinale polysaccharides in biological samples via 99mTc-labelling and radioHPGPC analysis. Carbohydrate Polymers. 367. 123935–123935. 2 indexed citations
6.
7.
Rao, Qiu, Y. Chen, Binghong Gao, et al.. (2024). 759P JSKN003, a HER2-targeting antibody-drug conjugate, in patients with platinum-resistant ovarian cancer: A pooled analysis of two studies. Annals of Oncology. 35. S575–S576. 3 indexed citations
8.
Pan, Xianglin, et al.. (2024). Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system. Frontiers in Pharmacology. 15. 1431579–1431579. 1 indexed citations
9.
Su, Hongyan, et al.. (2024). Post-marketing safety concerns of sotorasib: A disproportionality analysis based on FDA adverse event reporting system. Heliyon. 10(9). e30437–e30437. 3 indexed citations
10.
Shu, Yamin, et al.. (2023). Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system. Frontiers in Immunology. 14. 1169735–1169735. 23 indexed citations
11.
Zhang, Qilin, et al.. (2023). A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data. BMC Cancer. 23(1). 745–745. 16 indexed citations
12.
13.
Shu, Yamin, et al.. (2022). A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib. Scientific Reports. 12(1). 20601–20601. 53 indexed citations
14.
Shu, Yamin, Yufeng Ding, Xu‐Cheng He, et al.. (2022). Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China. Frontiers in Pharmacology. 13. 920479–920479. 8 indexed citations
15.
Shu, Yamin, Yanxin Liu, Xu‐Cheng He, Yufeng Ding, & Qilin Zhang. (2022). Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china. Frontiers in Pharmacology. 13. 818579–818579. 7 indexed citations
16.
17.
Shu, Yamin, et al.. (2022). A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax. PLoS ONE. 17(12). e0278725–e0278725. 19 indexed citations
18.
Shu, Yamin, Xu‐Cheng He, Yanxin Liu, Pan Wu, & Qilin Zhang. (2022). A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System. Clinical Epidemiology. Volume 14. 789–802. 106 indexed citations
19.
Shu, Yamin, Qilin Zhang, Xu‐Cheng He, & Li Chen. (2021). Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China. Cancer Management and Research. Volume 13. 8297–8306. 6 indexed citations
20.
Zhang, Qilin, Pan Wu, Xu‐Cheng He, Yufeng Ding, & Yamin Shu. (2021). Cost-Effectiveness Analysis of Camrelizumab vs. Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China. Frontiers in Oncology. 11. 790373–790373. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yufeng Ding Breakdown of academic impact, for papers by Maobai Liu Breakdown of academic impact, for papers by H. T. Schneider Breakdown of academic impact, for papers by Sooyoung Shin Breakdown of academic impact, for papers by Hervé Le Louët Breakdown of academic impact, for papers by Ikuya Miki Breakdown of academic impact, for papers by Vasco A. J. Maria Breakdown of academic impact, for papers by Andreas Benesic Breakdown of academic impact, for papers by Xuemin Jiang Breakdown of academic impact, for papers by Anton Gillessen
Rankless by CCL
2026